Allentown, PA, United States of America

Fouad Moussa

USPTO Granted Patents = 3 

Average Co-Inventor Count = 9.7

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Fouad Moussa: Innovator in Cancer Treatment

Introduction

Fouad Moussa is a notable inventor based in Allentown, PA, who has made significant contributions to the field of cancer treatment. With a total of three patents to his name, he has focused on developing innovative therapies that target specific cancer markers.

Latest Patents

Moussa's latest patents include the development of novel anti-CD28 x anti-PSMA antibodies. These antibodies are designed to treat PSMA-associated cancers by agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. This unique mechanism allows for enhanced anti-tumor activity at tumor sites while minimizing peripheral toxicity. The antibodies are particularly useful when combined with other anti-cancer therapies, such as anti-CD3 x anti-PSMA antibodies, for the treatment of prostate cancers.

Career Highlights

Throughout his career, Fouad Moussa has worked with prominent companies in the biotechnology sector, including Xencor, Inc. and Abzyme Therapeutics LLC. His work has been instrumental in advancing therapeutic options for cancer patients.

Collaborations

Moussa has collaborated with esteemed colleagues, including John R. Desjarlais and Gregory L. Moore, contributing to the development of innovative cancer therapies.

Conclusion

Fouad Moussa's work in developing anti-CD28 x anti-PSMA antibodies represents a significant advancement in cancer treatment. His innovative approach and collaborations highlight his commitment to improving patient outcomes in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…